Proteomics for prediction and characterization of response to infliximab in Crohn's disease: A pilot study

Clinical Biochemistry

Volumn 41, Issue 12, 2008, Pages 960-967

  Meuwis, Marie Alice ^a   Fillet, Marianne ^a   Lutteri, Laurence ^a   Marée, Raphaël ^a   Geurts, Pierre ^a   de Seny, Dominique ^a   Malaise, Michel ^a   Chapelle, Jean Paul ^a   Wehenkel, Louis ^a   Belaiche, Jacques ^b   Merville, Marie Paule ^a   Louis, Edouard ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Crohn's disease; Infliximab; PF4; Proteomics; Serum profiling

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CD40 LIGAND; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 6; PLATELET AGGREGATION FACTOR 4; PROTEIN DERIVATIVE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIVARIATE ANALYSIS; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; THROMBOCYTE METABOLISM; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CD40 LIGAND; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PILOT PROJECTS; PLATELET FACTOR 4; PROGNOSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 47049105521     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.04.021     Document Type: Article

References (24)

1. Rutgeerts P., Van Assche G., and Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126 (2004) 1593-1610
2. Rutgeerts P., Van Assche G., and Vermeire S. Review article: infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 23 (2006) 451-463
3. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
4. Kupcova V., Turecky L., Detkova Z., Prikazska M., and Keleova A. Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease. Physiol Res 52 (2003) 89-93
5. Dideberg V., Theatre E., Farnir F., et al. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet Genomics 16 (2006) 727-734
6. Gustot T., Lemmers A., Louis E., et al. Profile of soluble cytokine receptors in Crohn's disease. Gut 54 (2005) 488-495
7. Mascheretti S., and Schreiber S. The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease. Pharmacogenomics 5 (2004) 479-486
8. Hlavaty T., Pierik M., Henckaerts L., et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 22 (2005) 613-626
9. Louis E.J., Watier H.E., Schreiber S., et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 16 (2006) 911-914
10. Mitoma H., Horiuchi T., Hatta N., et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128 (2005) 376-392
11. Petricoin E.F., Ornstein D.K., and Liotta L.A. Clinical proteomics: applications for prostate cancer biomarker discovery and detection. Urol Oncol 22 (2004) 322-328
12. Coombes K.R., Morris J.S., Hu J., Edmonson S.R., and Baggerly K.A. Serum proteomics profiling-a young technology begins to mature. Nat Biotechnol 23 (2005) 291-292
13. de Seny D., Fillet M., Meuwis M.A., et al. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum 52 (2005) 3801-3812
14. Meuwis M.A., Fillet M., Geurts P., et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol 73 (2007) 1422-1433
15. Geurts P., Fillet M., de Seny D., et al. Proteomic mass spectra classification using decision tree based ensemble methods. Bioinformatics 21 (2005) 3138-3145
16. Lam Y.W., Mobley J.A., Evans J.E., Carmody J.F., and Ho S.M. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 5 (2005) 2927-2938
17. Gao Q., Meijer M.J., Schluter U.G., et al. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis 13 (2007) 693-702
18. Simi M., Leardi S., Tebano M.T., Castelli M., Costantini F.M., and Speranza V. Raised plasma concentrations of platelet factor 4 (PF4) in Crohn's disease. Gut 28 (1987) 336-338
19. Slungaard A. Platelet factor 4: a chemokine enigma. Int J Biochem Cell Biol 37 (2005) 1162-1167
20. Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin Thromb Hemost 30 (2004) 379-385
21. Danese S., Motte Cd Cde L., and Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 99 (2004) 938-945
22. Louis E., Vermeire S., Rutgeerts P., et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 37 (2002) 818-824
23. Danese S., de la Motte C., Sturm A., et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 124 (2003) 1249-1264
24. Danese S., Sans M., Scaldaferri F., et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 176 (2006) 2617-2624